Genomic characterization of MCL samples identified the loss of chromosome 9p21.1‐p24.3 containing SMARCA2, ARID2, and SMARCA4 genes in MCL patients who failed to respond to combined ibrutinib and venetoclax, suggesting that mutations in the SWI‐SNF chromatin‐remodeling complex mediate resistance to this combination in MCL [43]. The gene discussed is SMARCA2; the disease is mantle cell lymphoma.